All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EHA 2019 | Myeloma XI subgroup analysis of KCRd induction by molecular risk
Bookmark this article
To view this video in other languages, please play the video and click on the settings icon. Click on “subtitles/CC”, followed by “auto translate”, and then select your chosen language from the drop-down menu.
At the 24th Congress of the European Hematology Association (EHA), Charlotte Pawlyn from the Institute of Cancer Research, London, UK, presents a subgroup analysis of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRd) induction by molecular risk from the Myeloma XI study.
Dr. Pawlyn introduces the Myeloma XI trial which evaluated more than 4000 newly diagnosed transplant eligible patients with MM in 110 National Health Service (NHS) centers. The subgroup analysis of a patient population with genetic mutations showed similarly superior progression-free survival (PFS) with quadruplet, rather than triplet, therapy.
Myeloma XI subgroup analysis of KCRd induction by molecular risk
Your opinion matters
19 votes - 12 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox